ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Operating Expenses
ABL Bio Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Expenses
-₩119.1B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Operating Expenses
-₩1.3T
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-27%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Operating Expenses
-₩47.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Expenses
-₩36.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Expenses
-₩49.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-31%
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Operating Expenses
-₩36.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Operating Expenses?
Operating Expenses
-119.1B
KRW
Based on the financial report for Sep 30, 2025, ABL Bio Inc's Operating Expenses amounts to -119.1B KRW.
What is ABL Bio Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-27%
Over the last year, the Operating Expenses growth was -44%. The average annual Operating Expenses growth rates for ABL Bio Inc have been -31% over the past three years , -27% over the past five years .
